Fifty 1 Labs, Inc. is a Nevada-based holding company focused on health, wellness, and biotech through AI-driven drug repurposing and functional medicine. The Company operates subsidiaries including Fifty1 AI Labs LLC and 51 Labs LLC, which focus on personalized medicine, sports nutrition, and advanced therapeutics. Fifty1 AI Labs LLC delivers transformative solutions for patients and shareholders. 51 Labs LLC offers a line of supplements including pre-workout formulas, BCAAs, ION+ Electrolyte Formula, Turmeric Gummies, and Ashwagandha Gummies designed to enhance athletic performance, recovery, and overall health.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-07-24	US$0.000100	0.00%	1,215

Delayed Quote OTC Markets

More quotes

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - OTC Markets Other stock markets 11:57:08 2026-07-24 EDT			5-day change	1st Jan Change
0.000100 ^USD	0.00%		0.00%	-

01-05	Fifty 1 Labs, Inc. Announces CEO Changes	CI
25-08-14	Fifty 1 Labs, Inc. Announces the Completion of the Largest and Most Comprehensive Study of Sickle Cell Disease	CI

Market Cap	281K 247K 230K 212K 397K 26.99M 402K 2.74M 1.07M 13.33M 1.06M 1.03M 46.07M	P/E 2009	-0.05x	P/E 2010	-0.01x
Enterprise Value	12.55M 11.04M 10.27M 9.44M 17.72M 1.2B 17.95M 122M 47.69M 594M 47.13M 46.11M 2.05B	EV / Sales 2009	1.86x	EV / Sales 2010	2.41x
Free-Float	57.9%	Yield 2009 *	-	Yield 2010	-

01-05	Fifty 1 Labs, Inc. Announces CEO Changes	CI
25-08-14	Fifty 1 Labs, Inc. Announces the Completion of the Largest and Most Comprehensive Study of Sickle Cell Disease	CI
25-07-10	Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling 50 1 Labs, Inc. Toward $50 Million Valuation	CI
25-04-30	Fifty 1 Labs, Inc. Appoints Michael Lawson as Chairman of the Board	CI
25-04-30	Fifty 1 Labs, Inc. Appoints Michael Lawson as Chief Executive Officer	CI
25-04-30	The Fifty 1 Labs Biosentry Division Will Develop State-Of-The-Art Biohazard Sensing Sensors Capable of Detecting Pathogens	CI
25-04-30	UAV Corp. Announces Strategic Partnership with 50 1 Labs, Inc	CI
25-04-08	Uav Corp And Genetic Networks Announce Strategic Collaboration	RE
25-03-20	Fifty 1 Labs, Inc. Appoints Gennaro D'Urso as CEO	CI
25-03-20	Fifty 1 Labs, Inc. Appoints Gennaro D'urso as Chairman	CI
25-03-19	Fifty 1 Labs, Inc. acquired Genetic Networks, LLC for $0.02 million.	CI
25-03-14	Consumer Automotive Finance, Inc has Changed its Name to Fifty 1 Labs, Inc	CI
25-03-14	Fifty 1 Labs, Inc. has Changed its Ticker to FITY from CAFI	CI

07-10	Fifty 1 Labs Announces Strategic Evolution into Peptide Biotechnology and Telehealth	AQ
04-15	Fifty 1 Labs, Inc. Accelerates Peptide Biotechnology Push into Musculoskeletal Health	AQ
04-14	Fifty 1 Labs, Inc. Eliminates 612 Million Shares from the Market	AQ
01-05	Fifty1 Labs, Inc. Clarifies Status Regarding Previously Announced Collaboration with LUNR Aerospace	AQ
25-10-09	Fifty 1 Labs Inc. Appoints Dr. Joel Gagnier as Chief Science Officer	AQ

NOWAUTO INC Stock OTC Markets

Stocks

NWAU

US67012P1093

Biotechnology & Medical Research

Valuation: NOWAUTO INC

Chart: NOWAUTO INC

Latest news : NOWAUTO INC

Press Releases: NOWAUTO INC

Course Extremes

Managers and Directors: NOWAUTO INC

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

1 week	0		0
1 month	0		0
Current year	0		0
1 year	0		0
3 years	0		0.02
5 years	0		0.04
10 years	0		0.4

Manager	Title	Age	Since
Pritpaul Singh Arora CEO	Chief Executive Officer	47	-
Brandon Spikes PSD	President	-	-
Alind Gupta CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Robert Clark BRD	Director/Board Member	49	2025-04-29
Brandon Spikes CHM	Chairman	-	2023-07-11
Curtis Young BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NOWAUTO INC	0.00%	0.00%	-	-	711K
LONZA GROUP AG	+2.08%	-1.48%	-1.34%	+14.07%	46.86B
REVOLUTION MEDICINES, INC.	-0.61%	+4.26%	+404.75%	+647.20%	40.23B
BEONE MEDICINES AG	0.00%	+4.93%	+10.66%	+55.56%	36.23B
IQVIA HOLDINGS INC.	+2.48%	+4.57%	+7.82%	-5.05%	34.72B
CELLTRION, INC.	+0.62%	+1.65%	+5.41%	+43.89%	27.89B
MEDPACE HOLDINGS, INC.	-2.00%	+11.64%	+30.09%	+136.81%	16.79B
ASCENDIS PHARMA A/S	-0.17%	+0.66%	-	-	16.74B
EUROFINS SCIENTIFIC SE	+0.78%	-4.78%	-2.68%	+9.96%	13.12B
ICON PUBLIC LIMITED COMPANY	+1.82%	+1.56%	-11.01%	-30.15%	12.7B
Average	+0.45%	+0.97%	+55.46%	+109.04%	27.25B
Weighted average by Cap.	+0.62%	+1.05%	+75.96%	+139.15%

	2009	2010
Net sales	5.41M 4.76M 4.43M 4.07M 7.64M 519M 7.74M 52.64M 20.56M 256M 20.32M 19.88M 886M	5.11M 4.49M 4.18M 3.84M 7.21M 490M 7.3M 49.67M 19.4M 242M 19.17M 18.76M 836M
Net income	-2.23M -1.96M -1.83M -1.68M -3.15M -214M -3.19M -21.71M -8.48M -106M -8.38M -8.2M -365M	-1.89M -1.67M -1.55M -1.42M -2.67M -182M -2.71M -18.43M -7.2M -89.7M -7.11M -6.96M -310M
Net Debt	9.96M 8.75M 8.15M 7.48M 14.05M 955M 14.23M 96.84M 37.82M 471M 37.37M 36.57M 1.63B	12.27M 10.79M 10.04M 9.22M 17.32M 1.18B 17.55M 119M 46.63M 581M 46.07M 45.08M 2.01B